Top
Main

All outcomes

Feedback
Home
Show Outline
Top   Main   All Outcomes
Home   COVID-19 treatment studies for Zinc  COVID-19 treatment studies for Zinc  C19 studies: Zinc  Zinc   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
Loading...
Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc
Supplementary Data — Zinc for COVID-19: real-time meta analysis of 42 studies
Covid Analysis, June 28, 2022, DRAFT
https://c19zinc.com/meta.html
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Derwand 79% 0.21 [0.03-1.47] death 1/141 13/377 CT​2 Improvement, RR [CI] Treatment Control Derwand 82% 0.18 [0.07-0.54] hosp. 4/141 58/377 CT​2 Thomas (RCT) -44% 1.44 [0.36-5.71] hosp. 5/58 3/50 Thomas (RCT) 12% 0.88 [0.67-1.16] recov. time 58 (n) 50 (n) Asimi 97% 0.03 [0.00-0.44] ventilation 0/270 9/86 CT​2 Asimi 99% 0.01 [0.00-0.16] hosp. 0/270 24/86 CT​2 Asimi 100% 0.00 [0.00-0.08] severe case 0/270 51/86 CT​2 Mayberry 53% 0.47 [0.33-0.65] death 938 (n) 1,090 (n) Mayberry 64% 0.36 [0.27-0.47] ventilation 938 (n) 1,090 (n) Mayberry 60% 0.40 [0.31-0.52] ICU 938 (n) 1,090 (n) Mayberry 58% 0.42 [0.33-0.54] death/v/ICU 938 (n) 1,090 (n) Mayberry 85% 0.15 [0.10-0.22] progression 938 (n) 1,090 (n) Carlucci 38% 0.62 [0.46-0.84] death/HPC 54/411 119/521 Carlucci 18% 0.82 [0.54-1.25] ventilation 29/411 62/521 Carlucci 23% 0.77 [0.53-1.10] ICU 38/411 82/521 Krishnan 18% 0.82 [0.62-1.09] death 31/58 61/94 Yao 34% 0.66 [0.41-1.07] death 73/196 21/46 Frontera (PSM) 37% 0.63 [0.44-0.91] death 121/1,006 424/2,467 CT​2 Frontera (PSM) 24% 0.76 [0.60-0.96] death 121/1,006 424/2,467 CT​2 Abd-Elsalam (RCT) 1% 0.99 [0.30-3.31] death 5/96 5/95 Abd-Elsalam (RCT) 34% 0.66 [0.19-2.26] ventilation 4/96 6/95 Abd-Elsalam (RCT) 6% 0.94 [0.55-1.62] no recov. 20/96 21/95 Abd-Elsalam (RCT) 4% 0.96 [0.86-1.08] hosp. time 96 (n) 95 (n) Rosenthal -16% 1.16 [1.05-1.28] death n/a n/a Darban (RCT) 33% 0.67 [0.14-3.17] progression 2/10 3/10 ICU patients CT​2 Darban (RCT) 6% 0.94 [0.84-1.06] ICU 10 (n) 10 (n) ICU patients CT​2 Patel (DB RCT) 20% 0.80 [0.15-4.18] death 2/15 3/18 Mulhem 46% 0.54 [0.43-0.68] death 256/1,596 260/1,623 Gadhiya -41% 1.41 [0.69-2.57] death 21/54 34/229 Al Sulaiman (ICU) 36% 0.64 [0.37-1.10] death 23/82 32/82 ICU patients Al Sulaiman (ICU) 48% 0.52 [0.29-0.92] death 19/82 31/82 ICU patients Al Sulaiman (ICU) -25% 1.25 [0.84-1.87] ICU 82 (n) 82 (n) ICU patients Al Sulaiman (ICU) -6% 1.06 [0.85-1.33] hosp. time 82 (n) 82 (n) ICU patients Elavarasi 65% 0.35 [0.24-0.56] death 486 (n) 1,201 (n) Assiri (ICU) -81% 1.81 [0.41-6.97] death 10/60 4/58 ICU patients Kaplan (RCT) -14% 1.14 [0.08-16.6] ventilation 1/14 1/16 CT​2 Kaplan (RCT) -14% 1.14 [0.08-16.6] ICU 1/14 1/16 CT​2 Kaplan (RCT) -14% 1.14 [0.08-16.6] hosp. 1/14 1/16 CT​2 Zangeneh (ICU) -21% 1.21 [0.51-2.90] death n/a n/a ICU patients Alahmari 30% 0.70 [0.63-0.78] hosp. time 130 (n) 847 (n) Louca 1% 0.99 [0.93-1.06] cases Mahto 37% 0.63 [0.22-1.49] IgG+ 10/38 83/651 Holt 7% 0.93 [0.59-1.44] cases 21/750 425/14,477 Abdulateef 13% 0.87 [0.38-1.97] hosp. 7/111 23/317 Seet (CLUS. RCT) 50% 0.50 [0.34-0.75] symp. case 33/634 64/619 OT​1 Seet (CLUS. RCT) 27% 0.73 [0.41-1.05] cases 300/634 433/619 OT​1 Israel 100% 0.00 [0.00-0.89] hosp. case control CT​2 Bagheri 60% 0.40 [0.04-3.53] progression 33 (n) 477 (n) Bagheri 41% 0.59 [0.14-1.61] hosp. 4/33 167/477 Gordon 68% 0.32 [0.01-7.87] death 0/104 1/96 Gordon 85% 0.15 [0.02-0.58] symp. case 2/104 9/96 Kumar 20% 0.80 [0.21-2.99] death 6/75 3/30 Nimer -25% 1.25 [0.87-1.77] hosp. 41/326 178/1,822 Nimer -13% 1.13 [0.81-1.56] severe case 46/326 214/1,822 Shehab 47% 0.53 [0.19-1.47] severe case 4/65 22/188 Stambouli (DB RCT) 68% 0.32 [0.03-2.95] symp. case 1/59 3/56 Stambouli (DB RCT) 5% 0.95 [0.29-3.10] cases 5/59 5/56 Stambouli (DB RCT) 21% 0.79 [0.73-0.84] viral load 59 (n) 56 (n) zinc COVID-19 outcomes c19zinc.com Jun 2022 1 OT: comparison with other treatment2 CT: study uses combined treatment Favors zinc Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit